TARS — Tarsus Pharmaceuticals, Inc.

🔔 Alert me if TARS files an offering or S-3

Dilution risk: low; active automatic shelf (S-3ASR, Oct 2026). Float: 39.9M shares. Latest SEC filing: 10-Q on Nov 3, 2026. TARS closed at $72.64 (-0.93%) on Nov 3, 2026.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for TARS in the TickerWise workspace.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 323
• Website: https://www.tarsusrx.com

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Latest SEC filings for TARS

• 2026-11-0310-Q
• 2026-10-13S-3ASR
• 2026-10-13S-3ASR
• 2026-09-108-K
• 2026-08-13SCHEDULE 13G/A
• 2026-08-0610-Q
• 2026-08-068-K
• 2026-08-068-K
• 2026-08-068-K
• 2026-07-138-K

Latest TARS news

• 2026-11-04Tarsus expects $715M-$730M 2026 XDEMVY sales while deferring Europe and Japan filings Read article
• 2026-11-03Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates Read article
• 2026-11-03Tarsus Pharmaceuticals, Inc. GAAP EPS of -$14.40 misses by $10.38, revenue of $194.5M beats by $3.72M Read article
• 2026-11-02How Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78% Read article
• 2026-10-27Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline Read article
• 2026-10-06Tarsus Pharmaceuticals: XDEMVY Now Pays The Bills, And The Retina Deals Work Like Options Read article

Related companies

• VRTX — Vertex Pharmaceuticals Incorporated
• MRNA — Moderna, Inc.
• REGN — Regeneron Pharmaceuticals, Inc.
• ARGX — argenx SE
• ALNY — Alnylam Pharmaceuticals, Inc.
• INSM — Insmed Incorporated
• RVMD — Revolution Medicines, Inc.
• UTHR — United Therapeutics Corporation

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.